Current treatment options for AML/MDS, including conventional induction chemotherapy and HMAs +/− Ven, largely exert their efficacy via the induction of p53-mediated apoptosis (Schimmer et al, 2022; Thijssen et al, 2021). The gene discussed is TP53; the disease is myelodysplastic syndrome.